OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO
Events
You confirm that you have read our privacy policy. You can unsubscribe at any time by using the unsubscribe links.
